MedTrace Logo

JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

NCT04208464 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-10-18

No results posted yet for this study

Summary

This study aims to investigate the clinical efficacy of baricitinib in patients with adult idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will receive 24 weeks of baricitinib from the baseline visit with a 12 week follow-up period. The other half of patients will receive 24 weeks of barcitinib treatment after an initial 12-week delay with a 4 week follow up period for safety.

Conditions

  • Idiopathic Inflammatory Myopathies

Interventions

DRUG

Baricitinib

4mg daily for 24 weeks from baseline

DRUG

Baricitinib

4mg daily for 24 weeks starting after a 12-week treatment delay from baseline

Sponsors & Collaborators

Principal Investigators

  • Hector Chinoy · University of Manchester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-07
Primary Completion
2023-09-25
Completion
2023-09-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04208464 on ClinicalTrials.gov